[go: up one dir, main page]

CY1123754T1 - Ανασυνδιασμενο mycobacterium ως ενας ανοσοθεραπευτικος παραγοντας για τη θεραπεια του καρκινου - Google Patents

Ανασυνδιασμενο mycobacterium ως ενας ανοσοθεραπευτικος παραγοντας για τη θεραπεια του καρκινου

Info

Publication number
CY1123754T1
CY1123754T1 CY20211100030T CY211100030T CY1123754T1 CY 1123754 T1 CY1123754 T1 CY 1123754T1 CY 20211100030 T CY20211100030 T CY 20211100030T CY 211100030 T CY211100030 T CY 211100030T CY 1123754 T1 CY1123754 T1 CY 1123754T1
Authority
CY
Cyprus
Prior art keywords
treatment
cancer
immunotherapeutic agent
recombinant mycobacterium
recombinant
Prior art date
Application number
CY20211100030T
Other languages
English (en)
Inventor
Leander Grode
Original Assignee
Vakzine Projekt Management Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vakzine Projekt Management Gmbh filed Critical Vakzine Projekt Management Gmbh
Publication of CY1123754T1 publication Critical patent/CY1123754T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4524—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01005—Urease (3.5.1.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η εφεύρεση σχετίζεται με ένα κύτταρο ανασυνδυασμένου Mycobacterium για χρήση ως ένας ανοσοθεραπευτικός παράγοντας στη θεραπεία του καρκίνου, ιδιαίτερα στη θεραπεία στερεών όγκων. Ειδικότερα, η εφεύρεση σχετίζεται με την ανοσοθεραπεία του καρκινώματος της ουροδόχου κύστης.
CY20211100030T 2015-05-04 2021-01-15 Ανασυνδιασμενο mycobacterium ως ενας ανοσοθεραπευτικος παραγοντας για τη θεραπεια του καρκινου CY1123754T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15166206.1A EP3090757A1 (en) 2015-05-04 2015-05-04 Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
US201562387407P 2015-12-23 2015-12-23
PCT/EP2016/059872 WO2016177717A1 (en) 2015-05-04 2016-05-03 Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1123754T1 true CY1123754T1 (el) 2022-05-27

Family

ID=53054880

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100030T CY1123754T1 (el) 2015-05-04 2021-01-15 Ανασυνδιασμενο mycobacterium ως ενας ανοσοθεραπευτικος παραγοντας για τη θεραπεια του καρκινου

Country Status (24)

Country Link
US (2) US10525118B2 (el)
EP (2) EP3090757A1 (el)
JP (1) JP6778697B2 (el)
KR (1) KR102667859B1 (el)
CN (1) CN107864656A (el)
AU (1) AU2016258885B2 (el)
BR (1) BR112017023747A2 (el)
CA (1) CA2984602C (el)
CU (1) CU20170138A7 (el)
CY (1) CY1123754T1 (el)
DK (1) DK3291831T3 (el)
EA (1) EA036492B1 (el)
ES (1) ES2845724T3 (el)
HR (1) HRP20210107T1 (el)
HU (1) HUE052711T2 (el)
IL (1) IL255303B (el)
LT (1) LT3291831T (el)
MX (1) MX389038B (el)
PH (1) PH12017502011A1 (el)
PL (1) PL3291831T3 (el)
PT (1) PT3291831T (el)
RS (1) RS61333B1 (el)
SI (1) SI3291831T1 (el)
WO (1) WO2016177717A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102866709B1 (ko) * 2021-03-22 2025-10-02 클립스비엔씨 주식회사 신규한 재조합 마이코박테리움 스메그마티스 균주 및 이의 용도
MX2024000980A (es) * 2021-07-22 2024-06-21 Serum Life Science Europe Gmbh Mycobacterium recombinante como un agente inmunoterapeutico para la terapia de segunda linea contra carcinoma de vejiga urinaria.
EP4122491A1 (en) * 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733151A (en) 1996-08-23 1998-03-31 Edsall; David Electrical clamping connection device
ATE473238T1 (de) * 2003-04-23 2010-07-15 Max Planck Gesellschaft Tuberkulose vaccine mit verbesserter effizienz
AU2014210617B2 (en) * 2004-10-21 2016-07-21 Vakzine Projekt Management Gmbh Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
EP3360569B1 (en) * 2010-09-20 2020-03-18 Vakzine Projekt Management GmbH Recombinant mycobacterium as vaccine for use in humans
SMT201700046T1 (it) * 2010-12-21 2017-03-08 Max Planck Gesellschaft Micobatterio ricombinante come vaccino
US9678075B2 (en) * 2011-06-10 2017-06-13 Deutsches Krebsforschungszentrum Prediction of recurrence for bladder cancer by a protein signature in tissue samples
EP2620159A1 (en) * 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria

Also Published As

Publication number Publication date
EP3090757A1 (en) 2016-11-09
EP3291831A1 (en) 2018-03-14
WO2016177717A1 (en) 2016-11-10
DK3291831T3 (da) 2021-01-18
HRP20210107T1 (hr) 2021-03-19
US20200179502A1 (en) 2020-06-11
CN107864656A (zh) 2018-03-30
US20180200357A1 (en) 2018-07-19
CU20170138A7 (es) 2018-04-03
PT3291831T (pt) 2021-01-26
MX2017014142A (es) 2018-03-15
IL255303A0 (en) 2017-12-31
MX389038B (es) 2025-03-20
KR20170140328A (ko) 2017-12-20
PH12017502011A1 (en) 2018-03-26
JP2018520643A (ja) 2018-08-02
BR112017023747A2 (pt) 2018-07-31
JP6778697B2 (ja) 2020-11-04
RS61333B1 (sr) 2021-02-26
KR102667859B1 (ko) 2024-05-21
HUE052711T2 (hu) 2021-05-28
EA201792412A1 (ru) 2018-03-30
AU2016258885B2 (en) 2021-12-09
IL255303B (en) 2021-08-31
EP3291831B1 (en) 2020-12-30
US11426453B2 (en) 2022-08-30
HK1247574A1 (en) 2018-09-28
LT3291831T (lt) 2021-02-25
ES2845724T3 (es) 2021-07-27
SI3291831T1 (sl) 2021-03-31
AU2016258885A1 (en) 2017-11-23
CA2984602A1 (en) 2016-11-10
US10525118B2 (en) 2020-01-07
CA2984602C (en) 2023-09-05
PL3291831T3 (pl) 2021-05-31
EA036492B1 (ru) 2020-11-17

Similar Documents

Publication Publication Date Title
CL2023000812A1 (es) Péptidos, combinaciones y andamiajes para uso en inmunoterapia contra el cáncer divisional de solic.2017-02448
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
IL268888A (en) Multispecific binding proteins targeting caix, ano1, mesothelin, trop2, cea, or claudin-18.2
CY1122415T1 (el) Κυκλοπροπυλαμινες ως lsd1 αναστολεις
CR20170282A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
EA201891211A1 (ru) Ингибиторы cxcr2
PH12016501763B1 (en) Multispecific antibodies
BR112018005937A2 (pt) conjugados de oligonucleotídeo de afinidade e usos destes
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
BR112016007401A2 (pt) métodos e processos para avaliação não invasiva das variações genéticas
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
CL2018000756A1 (es) Métodos moleculares de aseguramiento de la calidad para su uso en la secuenciación
CY1123754T1 (el) Ανασυνδιασμενο mycobacterium ως ενας ανοσοθεραπευτικος παραγοντας για τη θεραπεια του καρκινου
EP3310915A4 (en) TUMOR IMMUNOTHERAPY
EA201591709A1 (ru) 5-бром-индирубины
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
BR112017002139A2 (pt) ?método para preparar um composto?
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
BR112018068798A2 (pt) composições e métodos para tratamento de doenças parasíticas
MX2020005454A (es) Tratamiento de cancer mejorado.
BR112019004276A2 (pt) métodos para o tratamento de câncer ovariano
SMT202100036T1 (it) Mycobacterium ricombinante come agente immunoterapico per il trattamento del cancro
UA111988U (uk) Ізомерні азовмісні біс-гідроксибензальдегіди з фрагментами тетрафторобензолу як мономери для азовмісних полімерів
TN2014000384A1 (fr) نظام صوتي ذكي وآمن